Skin infection

Verastem Oncology Announces Positive Initial Interim Safety and Efficacy Results from RAMP 205 Trial Evaluating Avutometinib Plus Defactinib in Combination with Gemcitabine and Nab-paclitaxel in First-Line Metastatic Pancreatic Cancer​

Retrieved on: 
torsdag, maj 23, 2024
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, Therapy, Sepsis, Patient, NAB, Retinal pigment epithelium, Bile, RAMP, Toxicity, ECOG, Febrile neutropenia, Verastem Oncology, Septic shock, BID, Clinical trial, Male, EDT, Avutometinib, Disease, Safety, Skin infection, Cancer, Pancreatic cancer, MMSc, Metastasis, ASCO, Anemia, Șaeș, Society, Eastern Cooperative Oncology Group, Mutation, Pulmonary embolism, Pneumoperitoneum, Webcast, BIW, Vomiting, DLT, Medicine, Annual general meeting, Phosphorus

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.

Key Points: 
  • Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with cancer, today announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2 clinical trial evaluating avutometinib plus defactinib in combination with gemcitabine and Nab-paclitaxel in the first-line in patients with metastatic pancreatic cancer.
  • We continue to progress the study evaluating other dose and schedule regimens to determine the recommended Phase 2 dose in the trial,” said John Hayslip, M.D., chief medical officer of Verastem Oncology.
  • “We look forward to Verastem presenting their initial data from the Phase 1b/2a trial of avutometinib and defactinib in combination with standard care gemcitabine and Nab-paclitaxel in previously untreated metastatic pancreatic cancer at ASCO.
  • Verastem will hold an investor conference call and webcast on Friday, May 24 at 8:00 am EDT, to discuss these data.

Solid Start to the Year: LEO Pharma Delivers 13% Revenue Growth Driven by Strong Performance in Dermatology

Retrieved on: 
fredag, maj 3, 2024
Science, Biotechnology, Research, Pharmaceutical, General Health, Health, Clinical Trials, Other Health, American Academy, Dermatitis, Phase, LEO, Risk, Delgocitinib, Annual report, Leo Pharma, Tralokinumab, Growth, DKK, Affiliation, CHE, Patient, Acquisition, Psoriasis, AAD, Skin infection, Multimedia, Marketing, Atopic dermatitis, Ichthyosis, Pharmaceutical industry

In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).

Key Points: 
  • In Q1 2024, LEO Pharma delivered a revenue growth of 13% in constant exchange rates (CER).
  • Dermatology revenue grew 16% to DKK 2,444 million (Q1 2023: 2,150 million), driven by growth of Adtralza®/Adbry® for atopic dermatitis (AD) and solid growth in the core portfolio.
  • “First quarter marks a solid start to 2024 with a 13% revenue growth and continued progress on our strategic priorities.
  • I am pleased with the strong growth track record for our global dermatology portfolio, primarily driven by performance in North America.

ADC Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Business Updates

Retrieved on: 
onsdag, mars 13, 2024
AXL, PIN, Neutropenia, Growth, Rituximab, Sarcoma, ALT, NSCLC, ASH, FY, Progression-free survival, Skin infection, Patient, Follicular lymphoma, S&M, Research, EDT, Aes, Periodic breathing, G&A, University, Lung cancer, Insurance, AACR, DLT, Pancreatic cancer, Hyperglycemia, Society, Therapy, Clinical trial, Diffuse large B-cell lymphoma, PFS, CD22, ADC, Data, Fatigue, MD Anderson Cancer Center, FDA, DLBCL, Marketing, PSMA, IDMC, Pharmaceutical industry

LAUSANNE, Switzerland, March 13, 2024 (GLOBE NEWSWIRE) -- ADC Therapeutics SA (NYSE: ADCT) today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided business updates.

Key Points: 
  • “In the fourth quarter we saw results of our strategy in action across a number of key areas.
  • A return to sequential quarter-over-quarter growth in the fourth quarter of 2023 followed the restructuring of the commercial model, with sales volume increasing in both community and academic settings.
  • R&D expenses were $30.3 million for the fourth quarter and $127.1 million for full year 2023, compared to $48.1 million and $186.5 million, respectively, for the fourth quarter and full year 2022.
  • ADC Therapeutics management will host a conference call and live audio webcast to discuss fourth quarter and full year 2023 financial results and provide a company update today at 8:30 a.m. Eastern Time.

Aditxt Signs a Definitive Agreement to Acquire Appili Therapeutics Inc., Developer of a Biodefense Vaccine Funded by the U.S. Department of Defense (DoD)

Retrieved on: 
tisdag, april 2, 2024
Health, Defense, Infectious Diseases, Pharmaceutical, Contracts, Biotechnology, Ulcer, Paromomycin, Patient, NTD, IND, Metronidazole, Francisella tularensis, Infection, OTCQX, Therapy, Priority review, USD, Risk, Systemic, NIH, Anthrax, Arrangement, World Health Organization, Investigational New Drug, Calendar, Scar, Neglected tropical diseases, Tablet, Public, Research, News, PRV, Acquisition, TSX, Drug development, Population health, Cutaneous leishmaniasis, Canada Business Corporations Act, FDA, Transaction, Government, Growth, Entrepreneurship, Skin infection, Share, Procurement, WHO, Pharmaceutical industry

The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.

Key Points: 
  • The U.S. FDA's approval of LIKMEZ highlighted Appili’s capacity to identify and develop significant opportunities within the infectious disease domain.
  • Appili licensed the manufacturing and commercialization rights in the U.S. and other selected territories to Saptalis Pharmaceuticals, LLC (“Saptalis”).
  • Appili, in collaboration with Saptalis, continued the product's development, ultimately achieving FDA approval in the United States.
  • With FDA approval, future revenue is expected to be derived from milestone payments and royalties from Saptalis under the license agreement.

Venture Capital Cross announces VC Portal Launch @ VCCross.com

Retrieved on: 
måndag, mars 25, 2024
Crypto, Andrew Ross Sorkin, Market, Astra, Home warranty, Skin infection, Education, Research, Fungus, Bacteria, AI, POC, Innovation system, Ice, FINRA, Artificial intelligence

KNOXVILLE, Tenn., March 25, 2024 /PRNewswire/ -- Venture Capital Cross @ vccross.com announces the launch of its cloud based private markets portal, where investors can access venture capital and private equity deals at any stage.

Key Points: 
  • KNOXVILLE, Tenn., March 25, 2024 /PRNewswire/ -- Venture Capital Cross @ vccross.com announces the launch of its cloud based private markets portal, where investors can access venture capital and private equity deals at any stage.
  • Venture Capital Cross is a division of COVA Capital Partners, LLC a registered broker-dealer and FINRA member, which has been developing a cloud based system to manage deal flow in any private market stage.
  • We believe that high growth is tied to high quality, and this complements our successful secondary market business," says Joseph Gelet Sr, Director of Private Markets for Venture Capital Cross.
  • Venture Capital Cross recently completed a Reg CF campaign for Free Speech platform Gab.com as well as secondary market transactions in Celonis, Dataminr, Addepar, Cerebras, Jasper AI, Weights & Biases, Neuralink, Anduril, and others.

AMERICAN ACADEMY OF DERMATOLOGY: HOW TO CHECK FOR BEDBUGS

Retrieved on: 
torsdag, mars 14, 2024
Biting, Skin infection, Chickenpox, Human, Anxiety, Seed, Thought, Rash, Skin, Allergy, FAAD, AAD, Blood, Bed bug, Frustration, Blister, Nail, Spider, Bed, Baggage

ROSEMONT, Ill., March 14, 2024 /PRNewswire/ -- Bedbugs can make you itch just by thinking about them. These tiny, reddish-brown insects that feed on blood are notorious for infiltrating hotel rooms and luggage, hitchhiking their way back to a new home virtually undetected.

Key Points: 
  • Although bedbug bites are not usually dangerous, bedbugs can come home with you, infest your home, and cause a great deal of discomfort and anxiety.
  • If bedbugs are present in your home, you will likely find bites on your body.
  • There are fewer spots for bedbugs to hide in bathrooms, so you can check your room without worry.
  • These tips are demonstrated in " How to check for bedbugs ," a video posted to the AAD website and YouTube channel .

Global Cephalosporin Drug Market Forecast to Reach USD 21.9 Billion by 2029: Exceptional Growth in Bacterial Infection Treatments Fuels Market Expansion - ResearchAndMarkets.com

Retrieved on: 
fredag, februari 23, 2024
General Health, Infectious Diseases, Health, Pharmaceutical, Clinical Trials, Generation, Urinary tract infection, Skin infection, Growth, SWOT, Skin, Respiratory tract infection, Administration, Prevalence, Knowledge, Infection, Pharmaceutical industry

A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.

Key Points: 
  • A sterling analysis of the global cephalosporin drug market has been conducted, encapsulating the various segments such as generation, route of administration, and application.
  • This report delves into the current industry patterns, the comprehensive competitive landscape, and the elaborative market dynamics from 2019 to 2029.
  • Highlighting the significance of bacterial infections as a driving force behind the growth of the cephalosporin drug market, the report underscores the increasing global demand for effective antibiotics.
  • With a robust forecast predicting substantial growth, this report is an essential asset for those seeking to navigate the complex pathways of the cephalosporin drug market.

Hugel Receives FDA Approval in the United States of Letybo (letibotulinumtoxinA-wlbg) for Injection for the Treatment of Glabellar Lines

Retrieved on: 
måndag, mars 4, 2024
Food and Drug Administration, Headache, MD, AB toxin, Catherine Disher, FDA, Blinking, Food, Vitamin, Dizziness, Hugel & Fils, Risk, Allergy, Human, Telecanthus, Rash, Patient, Skin infection, Child, Bleeding, Medication, Wheeze, Face, Pharmaceutical industry

NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults. In the coming months, Hugel plans to accelerate its transition for approved medical use with the goal of launching to aesthetic clinicians in the back half of 2024.

Key Points: 
  • NEWPORT BEACH, Calif., March 4, 2024 /PRNewswire/ -- Hugel America, Inc., a division of Hugel Inc., a global leader in the medical aesthetics industry, today announced it received United States (U.S.) Food and Drug Administration (FDA) approval on its neurotoxin, Letybo to treat moderate-to-severe glabellar (frown) lines in adults.
  • This is a huge achievement for Hugel as we focus on becoming a top aesthetics brand in the U.S.," stated James Hartman, President, Hugel America.
  • Joely Kaufman, MD, commented, "The results from the clinical trials for letibotulinumtoxinA demonstrate efficacy, and a convincing safety profile in the treatment of glabellar lines1.
  • FDA approval is supported by positive results from three completed phase III trials that enrolled more than 1,000 subjects in the U.S. and Europe1.

BOTOX® Cosmetic (onabotulinumtoxinA) Announces Its 2024 Grant Program Supporting Women Entrepreneurs

Retrieved on: 
onsdag, februari 21, 2024
Allergy, ABBV, Senior, Woman, Injection, Research, ALS, Paratriathlon, Headache, Neck pain, Workplace, Education, Catherine Disher, Dream, Vitamin, Small business, Dizziness, Mentorship, Asthma, AbbVie, Weakness, Risk, AB toxin, Pain, Face, Human, COMMUNITY, BIPOC, Postal, Eyebrow, Confidence, Rash, Skin infection, Breast milk, Burnout, Myasthenia gravis, Eyelid, Lambert–Eaton myasthenic syndrome, Medication, Wheeze, Fatigue, Xerostomia, Partnership, Pharmaceutical industry

IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs. BOTOX® Cosmetic partnered with IFundWomen to launch the program in 2023, and in the second year, will award a new group of 20 women entrepreneurs each with $25,000 grants to fund and grow their businesses. Additionally, BOTOX® Cosmetic continues to support these businesses through mentorship, coaching, crowdfunding, and community.

Key Points: 
  • FOR THE SECOND YEAR, BOTOX® COSMETIC WILL HELP WOMEN ENTREPRENEURS CLOSE THE CONFIDENCE GAP THROUGH FUNDING, MENTORSHIP, COACHING, AND COMMUNITY
    IRVINE, Calif., Feb. 21, 2024 /PRNewswire/ -- Today, Allergan Aesthetics, an AbbVie company (NYSE: ABBV), announced that applications are open for the 2024 BOTOX® Cosmetic grant program supporting women entrepreneurs.
  • We are grateful to learn from them and thrilled to continue this program into a second year with a new cohort of extraordinary women entrepreneurs."
  • I am forever grateful to this program for connecting me to a group of women entrepreneurs who together are helping to bridge the Confidence Gap.
  • Starting today, women entrepreneurs across the country can apply for the BOTOX® Cosmetic x IFundWomen grant at www.botoxcosmetic.com/realimpact for the chance to be one of 20 recipients.

U.S. Food and Drug Administration Approves ZELSUVMI™ as a First-in-Class Medication for the Treatment of Molluscum Contagiosum

Retrieved on: 
fredag, januari 5, 2024
Biotechnology, FDA, Health, Pharmaceutical, Clinical Trials, Food, FAAD, Molluscum contagiosum, Caregiver, Parent, American Academy, Skin infection, Nitric oxide, Patient, Viral, Clinical

Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.

Key Points: 
  • Ligand Pharmaceuticals Incorporated (NASDAQ: LGND) today announced that the U.S. Food and Drug Administration (FDA) has approved ZELSUVMI™ (berdazimer topical gel, 10.3%) for the treatment of molluscum contagiosum (molluscum) in adults and pediatric patients one year of age and older.i The FDA approved ZELSUVMI as the first novel drug for the treatment of molluscum infections.
  • vi
    “It is nice to see that molluscum contagiosum is finally getting the attention it deserves.
  • Nitric oxide has been shown to have antiviral properties.vii The mechanism of action of ZELSUVMI for the treatment of molluscum contagiosum is unknown.
  • With ZELSUVMI, patients now have an at-home treatment option available.”
    ZELSUVMI is expected to be available in the United States in the second half of 2024.